Utility of cell population data (VCS parameters) as a rapid screening tool for Acute Myeloid Leukemia (AML) in resource ‐constrained laboratories

Journal of Clinical Laboratory Analysis, EarlyView.
Source: Journal of Clinical Laboratory Analysis - Category: Laboratory Medicine Authors: Source Type: research

Related Links:

AbstractPurpose of ReviewThis review discusses the pathophysiology, risk factors, and the advances in the prevention or treatment of graft-vs-host disease (GvHD) by exploiting adjunct virotherapy. In addition, nonviral adjunct therapeutic options for the prevention of GvHD in the context of allogeneic hematopoietic stem cell transplantation (allo-HSCT) are discussed. The role of oncolytic viruses to treat different HSCT-eligible hematological cancers is also considered and correlated with the issue of GvHD in the context of allo-HSCT.Recent FindingsEmerging therapies focused on the prevention or treatment of GvHD include t...
Source: Current Pathobiology Reports - Category: Laboratory Medicine Source Type: research
We experienced therapy ‐related acute myeloid leukemia (t‐AML) in a patient with extensive disease‐small cell lung cancer (ED‐SCLC). This case is rare and has educational message because ED‐SCLC has a poor prognosis and often cannot survive until developing therapy related hematological malignancy. Furthermore t his case had unique chromosomal abnormalities. With recent advances in chemotherapy and radiotherapy, the prognosis of lung cancer has improved, while t‐AML has been increasing in frequency. Key Clinical MessageWe experienced therapy ‐related acute myeloid leukemia (t‐AML) in a patient with extensiv...
Source: Clinical Case Reports - Category: General Medicine Authors: Tags: CASE REPORT Source Type: research
AbstractPurpose of ReviewMinimal or measurable residual disease (MRD) detected by multiparameter flow cytometry (MFC) is an independent prognostic indicator in acute leukemia. However, the predictive value of MFC MRD is affected by technical challenges, interpretive complexities, and inadequate standardization, particularly in acute myeloid leukemia (AML). Here, we critically review the methodological principles of the MFC MRD assay and discuss clinical implications of MRD.Recent FindingsKey components of MFC MRD assays to be discussed include the principles of MFC, panel selection, analysis approaches, level of quantifiab...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research
Acute myeloid leukemia (AML)1 arises from clonal expansion of malignant hematopoietic precursor cells of the bone marrow. The broad variety of clinical features is the result of different alterations in multiple cellular pathways. This leads to a wide range of subgroups and different treatment options. Recent studies revealed distinct molecular subgroups of AML harboring single or combined somatic mutations [1]. The deletion of a portion of the long arm of chromosome 9, del(9q), is a recurring abnormality in malignant myeloid diseases reported in approximately 2% of AML cases [2].
Source: Leukemia Research - Category: Hematology Authors: Tags: Research paper Source Type: research
The ground-breaking study, led by the Leukemia&Lymphoma Society, is evaluating several novel targeted therapies for acute myeloid leukemia.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
We report here a novelRUNX1partner gene,KMT2C (MLL3), in a patient with de novo acute myeloid leukemia, having a novel and cytogenetically cryptic t(7;21)(q36.1;q22) leading to disruption ofRUNX1andKMT2C. This is the third crypticRUNX1 rearrangement in myeloid and the fourth in hematologic malignancies.Cytogenet Genome Res
Source: Cytogenetic and Genome Research - Category: Genetics & Stem Cells Source Type: research
Acute promyelocytic leukemia (APL) is characterized by the t(15;17) chromosomal translocation, leading to the formation of the promyelocytic leukemia-specific-retinoic acid receptor alpha (PML-RAR α or RARA) gene and is distinguished from other forms of PML by its responsiveness to all-trans retinoic acid (ATRA, also known as Tretinoin) therapy. It is a unique subtype of APL and accounts for about 10% of all acute myeloid leukemia (AML) cases in adults [1]. Promyelocytic leukemia was first d escribed in 1957 [2] as a fatal illness with a median survival time of less than a week.
Source: Leukemia Research - Category: Hematology Authors: Source Type: research
Inversion or translocation of chromosome 3, specifically inv(3)(q21q26.2/t(3;3)(q21;q26.2), is a recurrent finding in myeloid malignancies. These rearrangements usually result in elevated expression of the proto-oncogene MECOM (EVI1) at 3q26.2, through juxtaposition with a distal GATA2 enhancer. [1,2] Acute myeloid leukemia (AML) with inv(3)/t(3;3) is classified by the WHO as a distinct entity which can present de novo or arise from prior myelodysplastic syndrome (MDS) and is associated with aggressive disease, minimal or no response to chemotherapy, and short survival [3,4].
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Source Type: research
We report here a novelRUNX1partner gene,KMT2C (MLL3), in a patient with de novo acute myeloid leukemia, having a novel and cytogenetically cryptic t(7;21)(q36.1;q22) leading to disruption ofRUNX1andKMT2C. This is the third crypticRUNX1 rearrangement in myeloid and the fourth in hematologic malignancies.Cytogenet Genome Res
Source: Cytogenetic and Genome Research - Category: Genetics & Stem Cells Source Type: research
CONCLUSION:: Creation of a standardized antifungal prophylaxis program led to a marked decrease in LOS and the proven or probable IFI rate of patients with AML undergoing induction or reinduction chemotherapy. PMID: 30433844 [PubMed - as supplied by publisher]
Source: JOP - Category: Gastroenterology Authors: Tags: J Oncol Pract Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Laboratory Medicine | Leukemia